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The development of inflammatory dis-
eases implies inactivation of regulatory T
(Treg) cells through mechanisms that still
are largely unknown. Here we showed
that mast cells (MCs), an early source of
inflammatory mediators, are able to coun-
teract Treg inhibition over effector T cells.
To gain insight into the molecules in-
volved in their interplay, we set up an in
vitro system in which all 3 cellular compo-
nents were put in contact. Reversal of
Treg suppression required T cell–derived
interleukin-6 (IL-6) and the OX40/OX40L
axis. In the presence of activated MCs,
concomitant abundance of IL-6 and pau-
city of Th1/Th2 cytokines skewed Tregs
and effector T cells into IL-17–producing
T cells (Th17). In vivo analysis of lymph
nodes hosting T-cell priming in experi-
mental autoimmune encephalomyelitis re-
vealed activated MCs, Tregs, and Th17
cells displaying tight spatial interactions,
further supporting the occurrence of an
MC-mediated inhibition of Treg suppres-
sion in the establishment of Th17-medi-
ated inflammatory responses. (Blood.
2009;114:2639-2648)
Introduction
Traditionally associated with the allergic response, mast cells
(MCs) are now viewed as important players in a variety of immune
processes, such as pathogen clearance, graft acceptance, tumor
immunity, and many inflammatory and autoimmune diseases,
where they exhibit either pro- or anti-inflammatory potential
depending on the context.1 Interactions of MCs with T cells have a
functional role in some T cell–mediated pathologies, such as
neutrophilic airway inflammation,2,3 and autoimmune disease of
the central nervous system (CNS).4
MC-deficient mouse models show reduced development of both
allergic and neutrophilic airway hyperreactivity (AHR).2,3 MC-
derived tumor necrosis factor- (TNF-) is required for T helper
cell (Th17) development in the lung on ovalbumin (OVA) chal-
lenge of OTII transgenic mice,3 a neutrophilic AHR model strictly
dependent on interleukin-17 (IL-17).5 In multiple sclerosis, MCs
colocalize with demyelinating plaques in inflamed brain, and many
MC-associated markers have been detected in the affected tissue.6
The MC-deficient strain KitW/W-v shows decreased incidence and
severity of experimental autoimmune encephalomyelitis (EAE),
the rodent model of multiple sclerosis.7 MCs could be directly
activated during EAE by either the specific myelin peptides or
locally released agonists, including complement, cytokines, and
neuropeptides, but also indirectly stimulated via FcRI by specific
IgE elicited on activation of Th2 response.1,8 In the CNS, the local
release of inflammatory cytokines, proteases, oxygen radicals, and
chemokines by MCs directly contributes to myelin degradation,
disruption of the blood-brain barrier, and recruitment and activa-
tion of other immune cells as T lymphocytes and granulocytes in
the brain parenchyma, thus exacerbating the effector phase of
autoimmune response.4 MCs are also thought to be involved in
initiating EAE, through the interaction with dendritic cells and
T cells in secondary lymphoid organs.9
IL-17–secreting Th17 are considered one of the major patho-
genic immune components in both EAE10 and neutrophilic AHR.3
Th17 cells differentiate from uncommitted precursors on antigenic
activation and costimulation in the concomitant presence of a
suppressive and a pro-inflammatory signal delivered by transform-
ing growth factor- (TGF-) and IL-6 and/or IL-21, respectively.
Once primed in lymph nodes, pathogenic Th17 cells reach the
inflamed tissue where they recruit granulocytes and intensify
inflammation.11
Regulatory T cells (Tregs) are one of the most relevant sources
of TGF- both in vitro and in vivo. This CD4 T lymphocyte
subset, characterized by the constitutive expression of several
costimulatory molecules and the transcription factor Foxp3, is
endowed with immune-suppressive properties necessary to induce
and maintain tolerance.12 Recent findings support the notion of
Treg plasticity in vivo because inflammatory stimuli can counteract
Treg suppression and even promote differentiation into pathogenic
Th17 cells.13
MCs may directly or indirectly sustain the availability of
inflammatory signals that locally inhibit Treg suppression. The
cytokine IL-6, released by innate and adaptive cells on activation,
is known to break Treg anergy and suppression14 and to skew Tregs
into Th17 cells.13 Among MC-associated membrane molecules, the
costimulatory receptor OX40L can prevent de novo differentiation
of Tregs and block their function.15,16 Evidence of possible
MC-Treg interaction, through a variety of molecular mechanisms,
comes from different disease models17,18 and have been envisioned
in the pathogenesis of CNS autoimmune disease.4 Here we showed
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that, in vitro, MCs broke Treg anergy and suppression while
promoting Th17 cell differentiation, through mechanisms that
require IL-6 and OX40 engagement. We documented MC-Treg-
Th17 interaction in vivo in 2 different inflammatory conditions,
AHR and EAE, by showing IL-6–producing MCs in association
with TGF-–producing Tregs and IL-17–secreting effector T cells.
Colocalization of MCs with Tregs and Th17 cells could be detected
in lymph nodes draining the immunization site during EAE
initiation. Therefore, MCs appear to play a key role in the
development of deviated adaptive responses in inflammatory
diseases by inhibiting Treg suppression and modulating Th17
differentiation.
Methods
Mice and reagents
C57BL/6 WT and OTII transgenic mice were purchased from Charles
River. C57BL/6 CD45.1-congenic mice were from The Jackson Laboratory.
C57BL/6 OX40-deficient mice (Tnfrsf4/) were from Nigel Killeen
(University of California, San Francisco). Bone marrow and spleens from
C57BL/6 IL-6–deficient mice (il6/) were kindly provided by Juan Rivera
(National Institutes of Health, Bethesda, MD). Mice were maintained under
pathogen-free conditions at the animal facility of Fondazione Istituti di
Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori
(Milan, Italy). Animal experiments were authorized by the Institute Ethical
Committee of Fondazione Istituti di Ricovero e Cura a Carattere Scientifico
Istituto Nazionale dei Tumori and performed in accordance to institutional
guidelines and national law (DL116/92). Shipped mice were kept for 2 to
3 weeks in our facility before being entered into the experiments. 2,4-
Dinitrophenol (DNP)-specific IgE were kindly provided by Juan Rivera
(National Institutes of Health). Recombinant IL-6 and IL-3 were purchased
from PeproTech. Anti-IL-6R-blocking monoclonal antibody (clone 15A7)
was a kind gift of Gennaro Ciliberto (IRBM, Pomezia, Italy).
AHR induction and analysis
Neutrophilic airway hyperreactivity was induced in OTII mice by intranasal
injection of 50 g OVA (grade 5; Sigma-Aldrich) dissolved in 20 L
phosphate-buffered saline (PBS) once daily for 3 consecutive days.
Twenty-four hours after the last inhalation, bronchoalveolar lavage (BAL)
cells were collected and analyzed by flow cytometry.
EAE immunization and analysis
EAE was induced with MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) as
previously described.19 Briefly, MOG35-55 peptide was dissolved in PBS and
emulsified with an equal volume of incomplete Freund adjuvant supple-
mented with 4 mg/mL heat-killed Mycobacterium tuberculosis H37Ra
(Difco). Mice were injected subcutaneously with the peptide emulsion
containing 200 g of MOG35-55/mouse and, on the same day and 48 hours
later, injected intravenously with 200 ng of Bordetella pertussis Toxin (List
Laboratories) dissolved in PBS. Mice were assessed daily for clinical signs
of EAE according to a 5-point scale.19 Cell suspensions obtained from
spinal cords were resuspended in 37% isotonic Percoll, overlaid on 70%
isotonic Percoll, and centrifuged at 600g for 25 minutes. Pellets containing
enriched MC preparations were collected and extensively washed before
staining.
Histopathology and immunohistochemistry
Sections from formalin-fixed, paraffin-embedded lymph nodes and spinal
cords were stained with hematoxylin and eosin or Giemsa. Single-marker
immunohistochemistry was performed with the streptavidin-biotin-
peroxidase complex method using anti-IL-6 (M-19) or anti-IL-17 (H-132)
with either 3,3-diaminobenzidine or aminoethylcarbazole as chromogen.
Double immunostainings were performed by a 2-step single-staining
approach. The first stainings were performed using streptavidin-conjugated
alkaline phosphatase (LSAB kit; Dako) and Fast Red or nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate chromogenic substrates
(Dako). Second staining was performed by incubating slides with the
anti-Foxp3 (eBioscience) or anti-IL-17 and specific secondary horseradish
peroxidase–conjugated antibodies with either 3,3-diaminobenzidine or
aminoethylcarbazole as chromogen. All the immunostained sections (but
those involving nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phos-
phate chromogen) were counterstained with hematoxylin. Slides were
analyzed under a Leica DM2000 optical microscope, and microphoto-
graphs were collected using a Leica DFC320 digital camera.
BMMC–T-cell coculture and cytokine detection
Bone marrow-derived MCs (BMMCs) were differentiated in vitro from
bone marrow cells as described.20 After 5 weeks, BMMCs were monitored
for FcRI and c-kit expression by flow cytometry. Purity was usually more
than 97%; 106/mL BMMCs were sensitized in medium without IL-3 for
4 hours with 1 g/mL of DNP-specific IgE and then treated for 20 minutes
at 4°C with anti-CD16/CD32 (eBioscience). CD4CD25 (Teffs) or
CD4CD25 (Tregs) were purified from splenocytes with the CD25
T-cell isolation kit (Miltenyi Biotec) and labeled by incubation with 5 M
carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) for 15 minutes at
37°C. A total of 7.5  104/well Teffs and/or Tregs were cultured with
5  104 accessory cells (consisting of the whole spleen irradiated with
30 Gy) with or without 7.5  104/well BMMCs for 72 hours in complete
medium containing RPMI 1640 (Sigma-Aldrich) supplemented with 5%
fetal calf serum, 2 mM L-glutamine, 200 U penicillin, and 200 mg/mL
streptomycin (Sigma-Aldrich). For stimulation, 1 g/mL of purified anti-
CD3 (clone 145-2C11, eBioscience) was added. Where indicated, 100 ng/
mL DNP–human serum albumin (Sigma-Aldrich) was added (Ag).
Flow cytometry
Phycoerythrin (PE)–anti-CD45.2, PE-anti-OX40 (OX86), PE-Cy7-anti-
CD4, fluorescein isothiocyanate (FITC)– and PE-Cy7-anti–c-kit, and
FITC–anti-FcRI- (MAR-1) were purchased from eBioscience. BMMCs
were stained with purified anti-OX40L (RM134L, eBioscience) followed
by biotin–anti-rat IgG (Sigma-Aldrich) and PE-streptavidin (eBioscience).
Intracellular staining with PE-anti-Foxp3 (eBioscience), FITC-anti-
TGF-1 (1D11, RnD Systems), and Alexa Fluor 647–anti-IL17A (eBio-
science) was performed after 4 hours of stimulation in the presence of
monensin solution (eBioscience), 50 ng/mL phorbol myristate acetate, and
500 ng/mL ionomycin (Sigma-Aldrich). For evaluation of IL-6 secretion,
cells were stimulated for 4 hours with 5 g/mL brefeldin A (Sigma-
Aldrich), fixed in 2% PFA, stained with PE-anti–IL-6 (MP5-20F3; eBio-
science) in 0.5% saponin (Sigma-Aldrich), and then surface-stained.
Cytokine amounts in supernatants were analyzed through Cytokine Beads
Array (BD Biosciences; inflammation and Th1/Th2 cytokine kits) accord-
ing to the manufacturer’s instructions. Flow cytometry data were acquired
on a FACSCalibur (BD Biosciences) and analyzed with FlowJo software
(Version 8.5.2; TreeStar).
Statistical analysis
Results are expressed as the mean plus or minus SEM. Data were analyzed
using a nonpaired Student t test (Prism software; GraphPad).
Results
MCs inhibit Treg suppression and promote Treg and Teff
expansion
It is well documented that T-cell proliferation can be enhanced or
inhibited by MCs and Tregs, respectively.12,21 To investigate the net
effect of MCs and Tregs on the proliferation of nonregulatory
T cells, CD45.2 CD4CD25 effector T cells (Teffs) and CD45.1
CD4CD25 congenic Tregs were both labeled with CFSE and
2640 PICONESE et al BLOOD, 24 SEPTEMBER 2009  VOLUME 114, NUMBER 13
For personal use only.on October 13, 2016. by guest  www.bloodjournal.orgFrom 
polyclonally activated in the absence or presence of BMMCs,
either unstimulated or previously stimulated with IgE or IgE and
Ag. After 3 days, CD4 T cells were stained with CD45.2
antibody to discriminate CFSE dilution in the 2 T-cell popula-
tions. In the absence of Tregs, BMMCs increased Teff prolifera-
tion (from 69.33 	 2.00 to 94.70 	 1.67, P 
 .005), indepen-
dently from their activation status. Strikingly, BMMCs
significantly reduced the ability of Tregs to suppress the
proliferation of Teffs (from 17.76 	 1.35 to 65.75 	 2.68,
P 
 .001; Figure 1A-B). This effect was not simply the result of
BMMC-mediated Teff expansion because BMMCs significantly
reduced the rate of Treg suppression in each condition (from
74.39 	 1.41 to 26.67 	 3.71, P 
 .001; Figure 1A). BMMCs
inhibited Treg suppression in a dose-dependent fashion, as
proven by scaling down the BMMC/T-cell ratio (supplemental
Figure 1A, available on the Blood website; see the Supplemental
Materials link at the top of the online article).
Treg suppression and anergy are either similarly or differen-
tially regulated by antigen-presenting cells depending on the
experimental system.22-25 In the absence of BMMCs, we found
Tregs poorly proliferating while suppressing Teffs, as shown by
others.22,25 Notably, in the presence of BMMCs, Tregs exten-
sively proliferated even without Teffs (from 12.50 	 0.64 to
50.25 	 0.74, P 
 .001). Such proliferation was further en-
hanced when sensitized and Ag-activated BMMCs were added
to the culture (to 74.80 	 4.24, P 
 .005; Figure 1C-D). Teffs
synergized with BMMCs in enhancing Treg proliferation. In
addition, BMMC-mediated Treg expansion depended on the
BMMC/T-cell ratio (supplemental Figure 1B).
Overall these data suggest that BMMCs break Treg anergy and
suppressive function, allowing Teff proliferation.
MC-mediated inhibition of Treg suppression requires IL-6 and
OX40
The cytokine IL-6 has been associated with reversal of Treg
anergy,24 suppression,14 and phenotype13; therefore, it is a suitable
candidate for BMMC-mediated inhibition of Treg functions. In-
deed, the addition of an antibody blocking IL-6R (clone 15A7)
reverted, in a dose-dependent manner, BMMC-induced Teff and
Treg expansion and rescued Treg suppressive function (Figure
2A-B). Both Teffs and BMMCs could be sources of IL-6. BMMCs
produced IL-6 only when IgE-sensitized and Ag-stimulated, regard-
less of the presence of Tregs and/or Teffs (Figure 2C). Conversely,
Teffs produced IL-6 when stimulated with BMMCs, independently
from their activation and from the concomitant presence of Tregs
(Figure 2D).
To discriminate the role of IL-6 derived from BMMCs or Teffs,
il6/ mice were used as source of BMMCs or of Teffs. IL-6–
deficient BMMCs were still able to revert Treg anergy and
suppression similarly to their WT counterpart. On the contrary,
IL-6 deficiency in Teffs restored Treg suppression in the presence
of BMMCs, without significantly affecting Treg expansion (Figure
2E-F). We concluded that Teffs were the functionally relevant
source of this cytokine. Nonetheless, IL-6 effect on Treg functions
was detectable only in the presence of BMMCs.
Molecular mechanisms underlying BMMC-Teff cooperation in
the inhibition of Treg function may include both soluble and
membrane-associated signals. Indeed, besides IL-6, several costimu-
latory molecules associated with the cell surface have been
functionally linked to the reversal of Treg suppression.22,23 Further-
more, IL-6 might regulate the expression of the membrane
receptors possibly involved in BMMC–T-cell crosstalk. Among
Figure 1. BMMCs expand both Teffs and Tregs and inhibit Treg
suppression. CD45.2 Teffs and CD45.1 Tregs were CFSE-labeled and
polyclonally activated in the presence of unstimulated, IgE-sensitized, or
IgE-Ag–challenged BMMCs. After 72 hours, CFSE dilution in gated Teffs
or Tregs was evaluated by flow cytometry as a function of proliferation.
(A) Percentage of proliferating (CFSElow) Teffs. Numbers above bars
indicate percentage inhibition of Tregs in each condition. (B) Representa-
tive histogram plots showing CFSE dilution in Teffs in the absence (filled
areas) or presence (solid lines) of Tregs. (C) Percentages of proliferating
(CFSElow) Tregs. (D) Representative histogram plots showing CFSE
dilution in Tregs in the absence (solid lines) or presence (filled areas) of
Teffs. *P 
 .05, compared with the corresponding condition in the absence
of BMMCs. °P 
 .05, compared with the corresponding condition in the
absence of Ag stimulation to BMMCs. All data are from 1 representative of
3 independent experiments.
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costimulatory molecules that can bridge such interaction, the
OX40L/OX40 axis has been recognized capable of bidirectional
signaling. Indeed, the expression of OX40L on BMMCs is
constitutive and tunable by soluble factors, such as TNF-.21
OX40L interacts with OX40 (encoded by Tnfrsf4 gene) on the
surface of activated Teffs, boosting their proliferation and
survival.26 On the Treg side, OX40 is constitutively expressed
and conveys functional inhibition on triggering.15,16 We have
recently uncovered that Tregs suppress BMMC histamine
degranulation, but not cytokine secretion, through OX40L
signaling.18 Based on these premises, we tested whether OX40
expression on Tregs and Teffs was modulated in the coculture
with BMMCs. In the presence of BMMCs, in line with the
proliferation rate, Teffs expressed high or low levels of OX40 in
the absence or in the presence of Tregs, respectively (Figure
3A). Contrary to Teffs, but in line with their own proliferation
rate, Tregs expressed high levels of OX40 that became even
brighter in the presence of BMMCs and/or Teffs (Figure 3A).
The distinct effect of OX40 triggering on Teffs and Tregs was
investigated by coculturing BMMCs with each T-cell subset
from WT or Tnfrsf4/ donors. In the absence of BMMCs,
Tnfrsf4/ Teff proliferation and Tnfrsf4/ Treg suppression
were slightly reduced compared with their WT counterparts,
according to previous results.16,27 In the presence of BMMCs,
Teff expansion by BMMCs was minimally affected by OX40
deficiency. Strikingly, only if both Tregs and Teffs were
OX40-deficient, Treg suppression was partially restored despite
BMMCs addition (Figure 3B). This suggested that OX40
triggering might reduce Teff susceptibility to Treg suppression
on the one hand, while directly hindering Treg function on the
other. It also might imply that both events were concurrently
needed to establish the level of T-cell activation. Thus, OX40L
on MCs was shown to be a key signal that maximized the
immune response by acting on both Tregs and Teffs, as we have
shown in antitumor immunity.28 We observed no relevant effect
of OX40 in BMMC-mediated Treg proliferation (Figure 3C).
Figure 2. Roles of T-cell-derived IL-6 in BMMC effects. (A-B) CD45.2
Teffs and CD45.1 congenic Tregs, both CFSE-labeled, were cultured with
BMMCs. Where indicated, IL-6R–blocking monoclonal antibody (clone
15A7) was added scaling the final concentration at 50, 20, 10, or 5 g/mL.
As control, no antibody or an isotype-matched antibody (Ig) was added.
After 72 hours, CFSE dilution as a function of proliferation was evaluated
in gated Teffs (A) or Tregs (B). Percentages of CFSElow cells are indicated
in each subset. Data are from 1 representative of 2 independent experi-
ments. (C-D) BMMCs were left unstimulated, IgE-sensitized, or IgE-Ag–
activated and cultured alone or with equal numbers of Tregs, Teffs, or both,
in the presence of anti-CD3 to stimulate T cells, for 20 hours. IL-6
intracellular staining was performed on gated BMMCs (CD4 cells) (C) or
Teffs (D) in the coculture. Representative plots are here shown of 2
independent experiments. (E-F) WT CD45.2 Teffs and CD45.1 Tregs were
CFSE labeled and stimulated in the presence of WT or il6/ BMMCs.
Alternatively, il6/ CD45.2 Teffs were used. After 72 hours, CFSE dilution
was evaluated by flow cytometry in gated Teffs (E) or Tregs (F). Numbers
above bars indicate percentage inhibition of Tregs in each condition.
*P 
 .05, compared with the corresponding condition with WT BMMCs
and WT Teffs. Data are from 1 representative of 2 independent experi-
ments.
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On BMMCs, OX40L expression was detectable regardless of
IgE sensitization or IgE-Ag activation while down-regulated after
72 hours in vitro unless BMMCs were cocultured with Teffs but not
Tregs (Figure 3D-E). Interestingly, addition of recombinant IL-6
could substitute Teffs in maintaining high levels of OX40L in a
dose-dependent fashion, suggesting that Teff-derived IL-6 might
amplify BMMC–T-cell cross-talk through a prolonged OX40L/
OX40 interaction (Figure 3E). Thus, the OX40/OX40L axis is
sustained by IL-6 and contributes to BMMC-driven blockade of
Treg function.
MCs organize the cytokine milieu favorable to Th17 cell
differentiation
It has been previously reported that, under some circumstances,
Tregs can suppress cytokine production without affecting T-cell
proliferation.22,25 To characterize the BMMC-mediated Treg inhibi-
tion, we analyzed the array of cytokines detectable in supernatants
of BMMC–T-cell cocultures. The release of Teff-associated cyto-
kines, such as IL-2, interferon-, and IL-4, although increased in
the presence of BMMCs, was inhibited by Tregs (Figure 4A).
However, Tregs did not inhibit the release of proinflammatory
cytokines, such as IL-6, TNF-, and monocyte chemoattractant
protein-1 (not shown). Thus, in the presence of BMMCs, Tregs
were still able to inhibit Th1 (IL-2 and interferon-) and Th2 (IL-4)
cytokine production, although they were unable to suppress Teff
proliferation and the release of proinflammatory mediators, as well
as to preserve their own anergic condition.
Hampered Th1/Th2 differentiation and availability of IL-6 and
TNF- and of Treg-derived TGF- may favor Th17 differentia-
tion.13 To investigate this possibility, we evaluated the IL-17
intracellular content in CD45.2 Teffs and CD45.1 Tregs after
3 days of coculture. Addition of IgE-Ag–activated, but not resting,
BMMCs induced IL-17 production in Teffs only if Tregs were part
of the trio. Conversely, the percentage of IL-17–producing Tregs
was increased by IgE-Ag–stimulated BMMCs (from 0.39 	 0.14
to 4.57 	 0.59, P 
 .001) independently from the presence of Teffs
(Figure 4B). Surprisingly, BMMCs also produced IL-17, and their
contribution became evident in testing IL-17 content by enzyme-
linked immunosorbent assay in the 3-cell culture supernatants
(supplemental Figure 2).
In summary, these data suggest that activated BMMCs turn
Tregs from anergic and suppressive into proliferating and IL-17–
Figure 3. OX40/OX40L axis plays a role in BMMC functions. (A) OX40
expression and CFSE dilution in gated CD45.2 Teffs and CD45.1 Tregs
after 72 hours of coculture with BMMCs. (B-C) Proliferation of Teffs (B) and
Tregs (C) obtained from WT or Tnfrsf4/ mice, alternatively labeled with
CFSE, and seeded in different combinations, in the presence or not of
BMMCs. Numbers above bars indicate percentage inhibition of Tregs.
*P 
 .05, compared with the corresponding condition in the absence of
BMMCs. °P 
 .05, compared with the corresponding condition in the
presence of WT T cells. (D-E) OX40L expression in BMMCs after 24 or
72 hours of culture alone or in the presence of Teffs, Tregs, or both. When
indicated, BMMCs received scaled amounts of recombinant IL-6 (rmIL-6,
1, 5, 20, and 50 ng/mL). (E) Mean fluorescence intensity of OX40L staining
(relative to isotype staining) in BMMCs. *P 
 .05, compared with the same
condition at 24 hours. Data are from 1 representative of 2 independent
experiments.
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producing cells, an effect that spreads the pathogenic potential to
nearby T cells, which gain competence for proliferation and Th17
differentiation.
MCs colocalize in vivo with Tregs and Th17 cells in different
inflammatory conditions
To visualize the interactions engaged by MCs with Tregs and Th17
cells in vivo, we analyzed 2 well-characterized models of inflamma-
tory disease in which MCs and Th17 cells have a pathogenic role.
In transgenic OTII mice, intranasal ovalbumin challenge in-
duces the development of Th17 cells that are responsible for
neutrophil infiltration in the airways. BAL was harvested after
3 daily intranasal OVA injections (Figure 5A). More than 90% of
MCs, identified as c-kithigh FcRI cells, produced IL-6 (Figure 5B
middle panel). However, it should be noted that MCs were not the
only source of IL-6 among the collected cells, as also lymphocytes
produced IL-6 in vivo (Figure 5B right panel). The CD4
component of BAL cells included Th17 cells and Foxp3 Tregs, in
roughly similar proportion. A minority ( 1%) of double IL-17
Foxp3 cells was also detected. Intracellular staining revealed
active TGF- production by Foxp3 Tregs in vivo (Figure 5C).
Therefore, IL-6–producing MCs and TGF-–producing Tregs
populate the same inflammatory milieu in association with skewed
Th17 effector cells.
EAE is a model of autoimmunity involving MCs,7 Th17,29 and
Tregs30 participation, at least in the effector phase. The frequency
and the behavior of these cells were analyzed in draining lymph
nodes (DLNs) and spinal cord (SC), at the acute phase of
MOG35-55-induced EAE. This setting allowed distinguishing be-
tween the priming site and the target organ of the disease. The
frequency of c-kit FcRI MCs was sizeable in DLNs (Figure 6A
top panels) and SC (Figure 6B top panels) during disease onset.
A relevant proportion (8.53% 	 3.49%) of DLN-populating MCs,
but very few (0.11% 	 0.12%) of CNS-residing MCs, actively
produced IL-6 in the acute phase, indicating that they might affect
Th17 cell priming and differentiation primarily at the immuniza-
tion site (Figure 6A-B top panels). However, MCs were not the
only source of IL-6 in any condition analyzed (not shown),
indicating that also in vivo other cells, probably T cells, might be
an important source for this cytokine. Among CD4 T cells, Th17
cells accumulated preferentially in DLNs rather than in SC at the
acute phase (Figure 6A-B bottom panels) while recruited to SC at
more advanced stages (not shown). Foxp3 Tregs, detected in both
DLNs and SC, were actively producing TGF- (Figure 6A-B
bottom panels). Notably, a minority (
 0.5%) of IL-17 Foxp3
double-positive T cells were detected, supporting the idea that
Tregs may differentiate into Th17 cells in an inflammatory
microenvironment.13,31
The tissue distribution, the reciprocal relationship, and the
molecular products of Th17 cells, Tregs, and MCs were then
Figure 4. BMMCs create an optimal cytokine milieu for differentiation of Th17
cells. (A) Teffs were activated alone or in the presence of Tregs, and IgE-Ag–
activated BMMCs were added or not to the T-cell culture. After 72 hours, superna-
tants were collected and analyzed for cytokine production. Among all cytokines
analyzed, those showing significant variation between different groups are shown.
*P 
 .05, compared with the corresponding condition in the absence of BMMCs.
(B) CD45.2 Teffs and CD45.1 congenic Tregs were cultured alone or with unstimu-
lated, IgE-sensitized, or IgE-Ag–activated BMMCs in equal amounts. After 72 hours,
intracellular IL-17 content was evaluated by flow cytometry in each T-cell subset,
gated according to the respective CD45 variant. Data are from 1 representative of
2 (A) or 3 (B) independent experiments.
Figure 5. BMMCs, Tregs, and Th17 cells populate inflamed airways. AHR was
induced in OTII mice by intranasal OVA injection (A). BAL cells were collected
24 hours after the last inhalation. (B) Representative plots showing surface FcRI
expression and IL-6 intracellular content in gated CD45 c-kithigh (middle panel),
representing MCs among harvested BAL cells, and in gated CD3 lymphocytes (right
panel). Among gated CD4 cells, IL-17 versus Foxp3 expression is depicted (C).
Histogram shows intracellular TGF- expression in gated CD4Foxp3 Tregs (solid
line) compared with isotype control (filled area). The shown data are representative
from 3 experiments, each including at least 5 mice.
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analyzed by immunohistochemistry in lymphoid organs and CNS
of MOG35-55-immunized mice. The cytokine IL-6 was found as
intracellular product in DLNs and as both intracellular and
extracellular molecule in CNS (Figure 6C left). In DLNs, IL-6
cells were mostly found in the T-cell–rich paracortical area and
consisted of small- to medium-sized cells. Laser scanning confocal
microscopy for FcRI and IL-6 (Figure 6F) and immunohistochemi-
cal analysis of Giemsa-stained sections (supplemental Figure 3)
allowed the identification of some IL-6–producing MCs scattered
among IL-6 T cells in lymph nodes. Overall, most of the
IL-6–producing cells were FcRI and IL-6 signal in FcRI cells
was dimmer than that observed in FcRI cells, supporting a
prominent T-cell derivation of IL-6 (Figure 6F, supplemental
Figure 3). IL-17–producing cells were mainly found in DLNs
during acute phase and in perivascular lymphoid aggregates in SC.
Extracellular IL-17 was detected, especially in acutely inflamed SC
(Figure 6C right panels). Some IL-17–secreting cells were found in
close proximity to Foxp3 Tregs in DLNs, indicating that the 2 cell
types might establish cognate or direct interactions, as suggested,13
allowing Tregs to contribute to Th17 skewing (Figure 6E). Close
proximity was occasionally detected in DLNs between Tregs and
IL-6–secreting MCs and T cells, suggesting again that Tregs might
directly take part in innate and adaptive inflammatory response
(Figure 6D). Double immunohistochemistry for OX40 and IL-17
showed several IL-17–reactive cells among small clusters of
OX40-expressing lymphocytes (Figure 6G). In many cases, IL-17
cells were adjacent to one or more OX40 lymphocytes and some
IL-17–expressing cells showed surface reactivity to anti-OX40
(Figure 6G arrows). In conclusion, the MC-Tregs-Th17 interplay,
here documented in vivo, may be involved in the initiation, in
addition to the effector phase, of inflammatory diseases.
Discussion
It has been proposed that a proinflammatory microenvironment
may profoundly alter Treg program in vivo, which may be more
dynamic than so far perceived, but the link between Tregs and
inflammation, if functionally related, remains, mechanistically,
poorly understood. Innate immune cells may represent a significant
source of pro- and anti-inflammatory mediators both in situ and in
locoregional lymphoid organs. Poorly studied outside the allergy
field, MCs can orchestrate inflammation through a plethora of
soluble and cell surface molecules acting on nearby cells. Here we
showed, for the first time in inflamed tissues, the direct interaction
between MCs and Tregs in vivo in 2 disease models, such as AHR
and EAE. Such MC-Treg interaction was also detected in lymph
nodes draining the EAE immunization site, suggesting a role for
MCs in T-cell priming. In vitro, MCs reverted the anergic and
suppressive phenotype of Tregs and promoted a Th17-skewed
immune response. Soluble and contact-mediated mechanisms, such
as IL-6 and OX40/OX40L, respectively, were shown to take part in
this process.
Although confirming that BMMCs boosted Teff proliferation
and cytokine production in vitro,21 here we have added the
evidence that, in the presence of BMMCs, Tregs markedly
decreased their suppressive activity on Teffs. This might occur
because of an MC effect on Treg-intrinsic function and/or an MC
Figure 6. BMMCs, Tregs, and Th17 cells colocalize in EAE priming
and effector sites. EAE was induced in C57BL/6 mice by MOG35-55
immunization. Animals were killed after 10 days during the acute phase.
Lymph nodes draining the MOG35-55 injection site (DLN) and spinal cords
(SC) were analyzed by flow cytometry. (A) Representative dot plots
showing IL-6–producing cells among FcRIc-kit MCs (top panels) and
IL-17 versus Foxp3 expression in gated CD4 T cells (bottom panels) in
DLN of immunized mice. Histogram shows TGF- expression in gated
CD4Foxp3 Tregs (solid line) overlaid to isotype staining (filled area).
(B) Same analysis as in panel A, performed on SC samples.
(C) Formalin-fixed, paraffin-embedded sections obtained from DLN and
SC were evaluated by immunohistochemistry for IL-6 (left panels) and
IL-17 (right panels) expression (original magnification 200). (D-E) In
DLN, expression of Foxp3 (brown) versus IL-6 (red, D) or versus IL-17
(red, E) was analyzed. Insets show (at higher magnification) the proximity
of Tregs with Th17 cells or IL-6 cells (original magnification 200).
(F) Double fluorescence confocal microscopy for IL-6 (green) and FcRI
(red) reveals a few IL6 FcRI MCs (white arrows) scattered among IL-6
FcRI lymphocytes. The inset shows (at higher magnification) the
interaction between MCs and IL-6–producing T cells (original magnifica-
tion 200). (G) Double immunohistochemistry for OX40 (blue) and IL-17
(red) shows IL-17 cells (cytoplasmatic reactivity) intermingling with small
clusters of OX40 lymphocytes (membrane reactivity). IL-17–expressing
cells also showed some degree of reactivity to anti-OX40 on the cell
surface (arrows) Original magnification 200. Data are from 2 indepen-
dent immunization experiments, each including at least 7 mice.
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effect on Teff susceptibility to suppression. However, BMMCs
directly induced Treg proliferation and IL-17 production, even in
the absence of Teffs. Because Treg anergy and suppressive ability
may be functionally linked,23 this suggested that BMMCs might
directly affect Treg functional program. Nonetheless, Treg prolifera-
tion was further enhanced in the concurrent presence of BMMCs
and Teffs, suggesting that the BMMC effect on Tregs may be, at
least partially, the result of Teff boosting.
Germane was the BMMCs-induced reversal of Treg suppres-
sion restricted to responder T-cell proliferation because Teff
production of Th1/Th2 cytokines remained inhibited by Tregs.
Thus, a sort of “split” functional paralysis of Tregs can be
envisaged in this 3-cell system that, preserving Treg inhibition
of cytokine production, allows T-cell expansion that, once
blocked in the Th1/Th2 program, could deflect to alternative
differentiation pathways.
A sizeable pool of Tregs can be detected in lymphoid organs and
in tissues during inflammatory diseases, such as CNS in EAE and
hyperreactive airways in AHR. However, the in vivo role of Tregs
in these contexts remains largely unexplained. They can alterna-
tively, but not exclusively, suppress immune responses, without the
strength necessary to overcome pathology, or remain neutral
because blocked in their functions, or become detrimental being
shifted from a regulatory to a pathogenic phenotype. The first
possibility is sustained by disease exacerbation on Treg depletion.30
In favor of the second hypothesis, myelin-specific Tregs from
inflamed CNS are able to suppress ex vivo naive but not CNS-
derived encephalitogenic Teffs, producing TNF- and IL-6.32
Third, the role of Treg-derived TGF- in Th17 skewing13 suggests
that Tregs can take part in inflammatory diseases. It could be
proposed that Tregs are not irreversibly differentiated, but rather
plastic and tunable depending on the disease phase. Indeed, we
found that IL-17–gaining Tregs still retained high/intermediate
levels of Foxp3 expression in vitro (not shown), suggesting that
Tregs may transiently undergo a double-positive stage before
becoming purely inflammatory cells.31 Accordingly, ex vivo evalu-
ation of Treg function cannot reproduce their in vivo behavior that
is under the influence of locally released factors. However, the lack
of knowledge on Treg significance in inflammatory pathology
justifies the in vitro assay considering the multiple players operat-
ing in vivo.
We have dissected here the complex relationships of a 3-cell
culture comprising MCs, Tregs, and Teffs. Blockade of IL-6R
signal reverted BMMC effects in a dose-dependent manner,
indicating IL-6 as key factor unleashing Tregs from anergy and
inhibiting their suppressive function. The alternative use of il6/
mice as donors of BMMCs or Teffs indicated that IL-6-null
BMMCs, likewise the WT counterpart, still blocked Treg suppres-
sion. Instead, Tregs inhibited the proliferation of IL-6–deficient
Teffs despite the presence of IL-6 competent BMMCs. Of note,
IL-6R blockade reverted BMMC effects irrespective of their
activation status (not shown), thus correlating with the pattern of
IL-6 production in T cells rather than in BMMCs.
T-cell production of IL-6 was early in the coculture, but the
initial trigger for this activation remains unknown. A possibility is
that a strong costimulation conveyed by BMMCs promotes IL-6
secretion by Teffs that in turn initiate BMMC-mediated amplifica-
tion of the T-cell response. This likely occurs through the OX40/
OX40L pathway that takes part in later events rather than in early
triggering of the T-cell response. Indeed, the expression of OX40L
on BMMCs during 72-hour culture required the presence of Teffs
or the addition of recombinant IL-6, indicating that early Teff-
derived IL-6 sustains prolonged OX40 engagement. Accordingly,
the expression of OX40 on Teffs began 16 hours after activation,
thus excluding its role in earlier phases of BMMC–T-cell interac-
tion. As a candidate for such initial Teff activation, direct TCR
stimulation by anti-CD3 cross-linked on BMMC-associated Fc-
receptors was doubtful because Fc-blocked BMMCs were used.
Also excluded were the CD80/CD86 molecules that are not
expressed by BMMCs.21 In light of previous data showing that
BMMCs-derived TNF- boosted T-cell activation,21 we tested
TNF--null BMMCs that however phenocopied the WT counter-
parts in terms of Teff proliferation and Treg expansion/suppressive
function (not shown). Thus, a still unknown “magic bullet”
triggered IL-6 production in T cells that, sensed by innate compo-
nents such as MCs, instigated their complicity to amplify a
response only drafted by adaptive cells (for a summarizing model,
see supplemental Figure 4A).
The activation status of BMMCs had different impact on certain
T-cell functions. Indeed, increased Teff and Treg proliferation and
inhibition of Treg suppression occurred without difference when
unstimulated, IgE-sensitized, or IgE-Ag–activated BMMCs were
used. Conversely, only IgE-sensitized Ag-stimulated BMMCs
specifically induced Th17 arousal. IL-6 production by Teffs and
OX40L/OX40 expression levels remained unaltered regardless of
the presence of unstimulated or stimulated BMMCs, suggesting
that they might be involved in a nonpolarized T-cell activation
rather than in active Th17 skewing. We are tempted to speculate
that steady-state BMMCs have the intrinsic property to foster T-cell
activation, whereas their specific stimulation should be required to
induce their secretion of IL-6 but also of TNF- and IL-1, all
necessary for a complete Th17 response (supplemental Figure 4B).
We have recently shown that Tregs directly inhibit MC degranu-
lation in vitro and in vivo through OX40/OX40L reverse signaling
in the MC.18 Of note, Tregs were shown to suppress the release of
histamine-preformed granules, thus inhibiting immediate anaphy-
lactic response, without affecting TNF- granule secretion or IL-6
production. On the same line, some of us have recently found that
histamine might protect from EAE because mice unable to
synthesize histamine because of a genetic deficit in the histidine
decarboxylase develop exacerbated disease on MOG35-55 immuni-
zation.33 A recent report shows Tregs inhibiting FcRI expression
in MC,34 a process that may result in the impairment of certain MC
functions and, as a consequence, in altered T-cell activation.
However, we could not find any difference in FcRI expression on
MC, in coculture with or without Tregs (not shown), or in
Treg-depleted or replete animals in vivo.18 Thus, a sort of split
suppression seems to occur from Tregs to MCs; accordingly, Tregs
selectively suppress the release of protective mediators while
preserving MC secretion of proinflammatory cytokines. MC-Treg
interaction has a role in the tolerance to skin allograft, depending
on Treg-derived IL-9 that recruits and sustains MC infiltration into
the graft.17 In this setting, MCs maintain tolerance until forced to
degranulate. Again, different contexts may be characterized by split
tolerance and variable interactions between regulatory and inflam-
matory cells.
IL-6 and OX40 have been independently associated with the
same inflammatory diseases. il6/ mice develop milder EAE,
even though IL-21 can substitute IL-6 in Th17 induction.35
Tnfrsf4/ mice also show attenuated EAE,36 and administration of
an OX40/OX40L-blocking antibody has been shown to ameliorate
EAE symptoms.37 However, they have never been studied together
or in the context of MC-Treg interactions. Moreover, very little is
known about the contribution of OX40-expressing Tregs and Teffs
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in disease or about the mechanisms driving distinct molecular and
functional responses in the 2 T-cell subsets on the stimulation of a
shared molecule. Reconstitution of MC-genetically deficient mice
with WT or il6/ BMMCs will allow ascribing a precise role to
MC-derived IL-6 in disease. We plan to induce EAE in the widely
used MC-deficient strain KitW-sh/W-sh, even though we cannot
exclude that the defects in granulocytic populations described in
these mice38 may mask the actual role of MCs in EAE. In vivo, we
found both MCs and T cells producing IL-6 in close contact with
Tregs in EAE priming site. This suggests that multiple IL-6 sources
are possible and that MCs may promote EAE in the lymphoid
compartment during the initiation phase, rather than in the inflamed
tissue during effector phase; accordingly, BMMCs injected into
MC-deficient mice have been shown to rescue EAE susceptibility,
albeit unable to infiltrate CNS.9
The interplay between innate and adaptive immune cells
contributes to the complexity of autoimmune disorders. T cell–
initiated activation may evoke the aid of potent innate players, as
MCs, to subvert suppressive barriers, and even to transform
regulatory cells into cells with pathogenic activity. Thus, blocking
this harmful cascade would represent a suitable goal for treatment
of inflammatory disease. This complex picture requires further
investigation but warns the scientific community to avoid straight-
forward therapeutic approaches that block, instead of just selec-
tively limiting, MC functions.
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